Why Immuneering Corporation’s (IMRX) Stock Is Down 8.51%
As of Thursday, November 05, Immuneering Corporation’s IMRX share price has dipped by 8.51%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
| Share Statistics | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $226.7 | $213.9 | 30% |
|
| Shares Out (Mil) | 64.7 | 55.4 | 53% |
|
| Institutional Ownership | 77.9% | 93.3% | 47% |
|
| Float (Mil) | 49.3 | 40.6 | 46% |
|
| Beta | 0.46 | 0.98 | 25% |
|
| Avg Daily Volume (000s) | 783 | 597 | 65% |
|
| Price Change (52-week) |
(49.4%) | 40.9% | 20% |
|
| Growth | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (26.9%) | (10.7%) | 16% |
|
| EPS (5yr) | 18.0% | 15.5% | 65 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.407) | ($1.257) | ($1.641) | |
| Month Ago EPS | ($0.339) | ($1.119) | ($1.256) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.343) | ($1.120) | ($1.271) | |
| Year/Year Chg | 8.8% | (1.3%) | 35.3% | |
| Financials | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($67) | ($44) | 14% |
|
| EPS (TTM) | ($1.028) | ($1.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($169) | $-0 | 11% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $80 | $135 | 21% |
|
| Valuation | IMRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.35 | 1.97 | 40% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (31.4%) | (47.5%) | 16% |
|
| ROE | (33.5%) | (51.9%) | 19% |
|
| Liabilities to Assets | 7.6% | 29.7% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 11/18/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.1% |
| +/- S&P 500: | -5.3 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors